[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Tenax Therapeutics (TENX)

Tenax Therapeutics (TENX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 219,790
  • Shares Outstanding, K 17,198
  • Annual Sales, $ 0 K
  • Annual Income, $ -52,600 K
  • EBIT $ -56 M
  • EBITDA $ -56 M
  • 60-Month Beta 1.00
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.26

Options Overview Details

View History
  • Implied Volatility 97.48% (+12.51%)
  • Historical Volatility 80.75%
  • IV Percentile 37%
  • IV Rank 11.59%
  • IV High 236.76% on 03/25/26
  • IV Low 79.22% on 04/23/26
  • Expected Move (DTE 12) 0.40 (3.13%)
  • Put/Call Vol Ratio 5.80
  • Today's Volume 585
  • Volume Avg (30-Day) 185
  • Put/Call OI Ratio 0.22
  • Today's Open Interest 4,306
  • Open Int (30-Day) 2,833
  • Expected Range 12.38 to 13.18

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-0.40
  • Number of Estimates 4
  • High Estimate $-0.35
  • Low Estimate $-0.43
  • Prior Year $-0.28
  • Growth Rate Est. (year over year) -42.86%

Price Performance

See More
Period Period Low Period High Performance
1-Month
12.56 +1.75%
on 05/01/26
16.52 -22.64%
on 04/06/26
-3.22 (-20.13%)
since 04/01/26
3-Month
10.37 +23.24%
on 03/09/26
16.95 -24.60%
on 04/01/26
+0.27 (+2.16%)
since 01/30/26
52-Week
5.34 +139.33%
on 06/20/25
18.38 -30.47%
on 01/14/26
+7.05 (+123.04%)
since 05/01/25

Most Recent Stories

More News
Tenax Therapeutics Appoints Thomas R. Staab, II as Chief Financial Officer

Mr. Staab has over 25 years of financial and executive experience across the healthcare industry CHAPEL HILL, N.C., April 22, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax”...

TENX : 12.78 (-2.52%)
Tenax Therapeutics: Q4 Earnings Snapshot

Tenax Therapeutics: Q4 Earnings Snapshot

TENX : 12.78 (-2.52%)
Tenax Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Achieved randomization target of 230 patients in LEVEL study, topline data expected in third quarter of 2026 Initiated global Phase 3 LEVEL-2 clinical trial and opened long-term OLE study for patients...

TENX : 12.78 (-2.52%)
Tenax Therapeutics to Participate in the 2026 Leerink Partners Global Healthcare Conference

CHAPEL HILL, N.C., March 03, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax” or “Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical...

TENX : 12.78 (-2.52%)
Tenax Therapeutics to Participate in the Guggenheim Emerging Outlook Biotech Summit 2026

CHAPEL HILL, N.C., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax” or “Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical...

TENX : 12.78 (-2.52%)
Tenax Therapeutics Announces Result of Prespecifed Blinded Sample Size Assessment

Planned Review of Standard Deviation Demonstrates No Need to Increase Size of Ongoing LEVEL Study LEVEL On Track to Complete Enrollment in First Half of 2026; Topline Data Expected in Second Half...

TENX : 12.78 (-2.52%)
Tenax Therapeutics to Participate in Upcoming Investor Conferences

CHAPEL HILL, N.C., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company using...

TENX : 12.78 (-2.52%)
Tenax Therapeutics: Q3 Earnings Snapshot

Tenax Therapeutics: Q3 Earnings Snapshot

TENX : 12.78 (-2.52%)
Tenax Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Phase 3 LEVEL Study Ongoing, Enrollment Completion (230 Patients) Expected in First Half of 2026, with Topline Data Expected in Second Half of 2026 On Track to Initiate Second Phase 3 Study, LEVEL-2,...

TENX : 12.78 (-2.52%)
Tenax Therapeutics to Host Virtual KOL Call to Discuss TNX-103 (Oral Levosimendan) for the Treatment of PH-HFpEF

CHAPEL HILL, N.C., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company using...

TENX : 12.78 (-2.52%)

Business Summary

Tenax Therapeutics, Inc. is a specialty pharmaceutical company focused on developing and commercializing a portfolio of products for the critical care market. The Company specializes in creating pharmaceuticals and medical devices in the fields of oxygen therapeutics, blood substitutes, and liquid ventilation...

See More

Key Turning Points

3rd Resistance Point 13.97
2nd Resistance Point 13.65
1st Resistance Point 13.21
Last Price 12.78
1st Support Level 12.45
2nd Support Level 12.13
3rd Support Level 11.69

See More

52-Week High 18.38
Fibonacci 61.8% 13.40
Last Price 12.78
Fibonacci 50% 11.86
Fibonacci 38.2% 10.32
52-Week Low 5.34

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.